title: Acetylsalicylic Acid Resistance After Simultaneous Pancreas-Kidney Transplantation.
abstract: BACKGROUND
  The most common conditions leading to death after simultaneous pancreas-kidney transplantations (SPKs) are cardiovascular diseases. The aim of this study was to test the platelet aggregation inhibitor acetylsalicylic acid (ASA) resistance in patients after SPKs, including investigations into the triggering factors.
  
  
  METHODS
  Thirty-two patients (22 men, 10 women; overall age, 47.4 ± 8.6 years) were involved in our study and took 100 mg ASA per day. We used optical platelet aggregometry to detect resistance.
  
  
  RESULTS
  Resistance occurred in 40.6% of the study group. However, with the use of logistic regression analysis, the examined 24 factors did not show any significant correspondence with resistance.
  
  
  CONCLUSIONS
  The incidence of ASA resistance seems to be higher compared with other groups, but the triggering effect is still unproved. Clarifying this question should be important regarding the mortality- and morbidity-reducing capacity of antiplatelet drugs in the management of cardiovascular conditions.
authors.affiliation: First Department of Medicine, Medical School, University of Pecs, Pecs, Hungary.
authors.forename: D
authors.initials: D
authors.lastname: Praksch
authors.affiliation: First Department of Medicine, Medical School, University of Pecs, Pecs, Hungary.
authors.forename: B
authors.initials: B
authors.lastname: Sandor
authors.affiliation: Department of Surgery, Medical School, University of Pecs, Pecs, Hungary.
authors.forename: K K
authors.initials: KK
authors.lastname: Nagy
authors.affiliation: Department of Surgery, Medical School, University of Pecs, Pecs, Hungary.
authors.forename: M
authors.initials: M
authors.lastname: Viola
authors.affiliation: First Department of Medicine, Medical School, University of Pecs, Pecs, Hungary.
authors.forename: A
authors.initials: A
authors.lastname: Toth
authors.affiliation: First Department of Medicine, Medical School, University of Pecs, Pecs, Hungary.
authors.forename: K
authors.initials: K
authors.lastname: Toth
authors.affiliation: Department of Surgery, Medical School, University of Pecs, Pecs, Hungary.
authors.forename: P
authors.initials: P
authors.lastname: Szakaly
authors.affiliation: Department of Surgery, Medical School, University of Pecs, Pecs, Hungary. Electronic address: advarga88@gmail.com.
authors.forename: A
authors.initials: A
authors.lastname: Varga
mesh_terms: D000328:Adult; D000368:Aged; D001241:Aspirin / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000517:prevention & control; D004351:Drug Resistance; D005260:Female; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D016035:Pancreas Transplantation / Q000009:adverse effects*; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*
chemical_list: D010975:Platelet Aggregation Inhibitors; D001241:Aspirin